Target Information

General Information of This Target

Target ID	PATR0RIOXT
Target Name	Human Deoxyribonucleic acid (hDNA)
Function	Deoxyribonucleic acid (DNA) is a polymer composed of two polynucleotide chains that coil around each other to form a double helix. The polymer carries genetic instructions for the development, functioning, growth and reproduction of all known organisms and many viruses. DNA and ribonucleic acid (RNA) are nucleic acids. Click to Show/Hide

Full List of The ADC Related to This Target

Approved

Click To Hide/Show 3 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	Gemtuzumab ozogamicin	Gemtuzumab	CD33	N-acetyl-gamma-calicheamicin	AcButDMH	[1]
ADC Info	Inotuzumab ozogamicin	Inotuzumab	CD22	N-acetyl-gamma-calicheamicin	AcButDMH	[2]
ADC Info	Loncastuximab tesirine	Loncastuximab	CD19	SG3199	Mal-PEG8-Val-Ala-PABC	[3]

Phase 3

Click To Hide/Show 1 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	Trastuzumab duocarmazine	Trastuzumab	ERBB2	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[4]

Phase 3 (Terminated)

Click To Hide/Show 2 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	Rovalpituzumab tesirine	Rovalpituzumab	DLL3	SG3199	Mal-PEG8-Val-Ala-PABC	[5]
ADC Info	Vadastuximab talirine	Vadastuximab	CD33	SGD-1882	Mc-Val-Ala	[6]

Phase 2

Click To Hide/Show 2 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	Camidanlumab tesirine	Camidanlumab	IL2RA	SG3199	Mal-PEG8-Val-Ala-PABC	[7]
ADC Info	Vobramitamab duocarmazine	Vobramitamab	CD276	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[8]

Phase 2 (Terminated)

Click To Hide/Show 1 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	CMB-401	Anti-MUC1 mAb hCTM01	MUC1	N-acetyl-gamma-calicheamicin	Amide-based linker	[9]

Phase 1/2

Click To Hide/Show 2 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	ADCT-602	Epratuzumab	CD22	SG3199	Mal-PEG8-Val-Ala-PABC	[10]
ADC Info	Pivekimab sunirine	Pivekimab	IL3RA	sulfonated DGN462	Mal-adipamide-Ala-Ala	[11]

Phase 1

Click To Hide/Show 9 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	ADCT-701	HuBa-1-3D	DLK1	SG3199	BCN-HydraSpace-Val-Ala-PABC	[12]
ADC Info	ADCT-901	Olintatug	KAAG1	SG3199	Mal-PEG8-Val-Ala-PABC	[13]
ADC Info	BYON-3521	Undisclosed	MET	seco-DUBA	Mc-Val-Cit-PABC	[14]
ADC Info	BYON-4413	A humanized anti-CD123 IgG1 antibody	IL3RA	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[15]
ADC Info	CS5001	A human anti-ROR1 IgG1 monoclonal antibody	ROR1	Prodrug pyrrolobenzodiazepine dimer	b-glucuronide linker	[16]
ADC Info	DS-9606a	Undisclosed	CLDN6	modified PBD	Undisclosed	[17]
ADC Info	IKS-03	Undisclosed	CD19	Pyrrolobenzo diazepine prodrug	Tumor-cleavable linker	[18]
ADC Info	Mipasetamab uzoptirine	Mipasetamab	AXL	SG3199	BCN-HydraSpace-Val-Ala-PABC	[19]
ADC Info	TR1801-ADC	hD12	MET	SG3199	Mal-PEG8-Val-Ala-PABC	[20]

Phase 1 (Terminated)

Click To Hide/Show 26 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	ABBV-011	SC17	SEZ6	Valeric-acid-calicheamicin	Mc-PEG8-acid-labile linker	[21]
ADC Info	ADCT-502	Trastuzumab	ERBB2	SG3199	Mal-PEG8-Val-Ala-PABC	[22]
ADC Info	CMD-193	Anti-Lewis-Y mAb G193	Lewis Y	N-acetyl-gamma-calicheamicin	AcButDMH	[23]
ADC Info	DCLL9718S	MCLL0517A	CLEC12A	PBD dimer	Cleavable disulfide linker	[24]
ADC Info	DHES-0815A	MHES0488A	ERBB2	Pyrrolo[2,1-c][1,4]benzodiazepine monoamide (PBD-MA)	Cleavable disulfide linker	[25]
ADC Info	Glypican 3 ADC	Adnectins scaffold protein	GPC3	Tubulysin analog Tub	Mal-EBE-Mal	[26]
ADC Info	IMGN-779	Z4681A	CD33	DGN462	Sulfo-SPDB	[27]
ADC Info	Lintuzumab Ac-225	Lintuzumab	CD33	AC225	DOTA-P-toluene isothiocyanate	[28]
ADC Info	MDX-1203	MDX-1115	CD70	Seco-MED-A	Mal-Val-Cit	[29]
ADC Info	MEDI-2228	BCMA-Ab1	TNFRSF17	SG3199	Mal-PEG8-Val-Ala-PABC	[30]
ADC Info	MEDI-3726	J591	FOLH1	SG3199	Mal-PEG8-Val-Ala-PABC	[31]
ADC Info	MEDI-7247	Idactamab	SLC1A5	SG3199	Mal-PEG8-Val-Ala-PABC
ADC Info	PF-06647263	Anti-EFNA4 mAb huE22	EFNA4	N-acetyl-gamma-calicheamicin	AcButDMH	[32]
ADC Info	Rolinsatamab talirine	Rolinsatamab	PRLR	SGD-1882	Mc-Val-Ala	[33]
ADC Info	SC-002	Rovalpituzumab	DLL3	SG3199	Val-Ala dipeptide linker	[34]
ADC Info	SC-004	Undisclosed	CLDN6; CLDN9	PBD dimer	Mc-Val-Cit-PABC	[35]
ADC Info	SC-005	Undisclosed	Undisclosed	PDB	Undisclosed
ADC Info	SC-006	Undisclosed	RNF43	SC-DR003	Valine-alanine	[36]
ADC Info	Serclutamab talirine	Serclutamab	EGFR	SGD-1882	Mc-Val-Ala	[37]
ADC Info	SGN-CD123A	Anti-CD123 mAb h7G3ec	IL3RA	SGD-1882	Mc-Val-Ala	[38]
ADC Info	SGN-CD19B	Anti-CD19 mAb hBU12ec	CD19	SGD-1882	Mc-Val-Ala	[39]
ADC Info	SGN-CD352A	Anti-SLAMF6 mAb h20F3ec	SLAMF6	PBD dimer	Valine-alanine	[40]
ADC Info	SGN-CD70A	Undisclosed	CD70	PBD dimer	Valine-alanine	[41]
ADC Info	SYD-1875	SYD1594	TPBG	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[42]
ADC Info	TAK-164	5F9	GUCY2C	DGN549	Mal-adipamide-Ala-Ala	[43]
ADC Info	Tamrintamab pamozirine	Tamrintamab	DPEP3	SC-DR002	Mc-Val-Ala-PABC	[44]

Investigative

Click To Hide/Show 664 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	¹¹¹In-1849	Anti-TF mAb 1849	F3	Indium-111	Undisclosed	[45]
ADC Info	¹¹¹In-DOTA-5D3	Anti-PSMA mAb 5D3	FOLH1	Indium-111	Tetraxetan	[46]
ADC Info	WO2021044208A1 ADC A2F2 M1-6	Anti-ROR1 mAb A2F2 M1	ROR1	SG2000	WO2021044208A1_ADC A2F2 M1-6 linker	[47]
ADC Info	WO2021044208A1 ADC A2F2 M1-6	Anti-ROR1 mAb A2F2 M1	ROR1	SG2000	WO2021044208A1_ADC A2F2 M1-7 linker	[47]
ADC Info	40H3-Tesirine	Anti-EGFR mAb 40H3	EGFR	SG3199	Mal-PEG8-Val-Ala-PABC	[48]
ADC Info	ABBV-322	Depatuxizumab S238C	EGFR	PBD dimer	Mc-Val-Ala	[49]
ADC Info	ABT-700 (S238C)-PBD	Telisotuzumab	MET	PBD dimer	Mc-Val-Ala	[50]
ADC Info	ACD22-LC-K149C-10	Anti-CD22-LC-K149C	CD22	PA-seco-CBI-dimer	Mc-cBu-Cit	[51]
ADC Info	Adalimumab fosimdesonide	Adalimumab	TNF	SGD-1882	Undisclosed	[52]
ADC Info	Adalimumab-Compound 43	Adalimumab	TNF	PBD dimer	Adalimumab-Compound 43 linker	[53]
ADC Info	Adalimumab-Compound 49	Adalimumab	TNF	PBD dimer	Adalimumab-Compound 49 linker	[53]
ADC Info	Adalimumab-Compound 74	Adalimumab	TNF	PBD dimer	Adalimumab-Compound 74 linker	[53]
ADC Info	ADC Trast-11	Trastuzumab	ERBB2	PBD dimer 3	Bis-BCN-modified Val-Cit-PABC linker 10	[54]
ADC Info	ADC Trast-14	Trastuzumab	ERBB2	PBD dimer 3	Undisclosed	[54]
ADC Info	ADCT-211	Anti-IL13RA2 mAb huCl47	IL13RA2	SG2000	Vali-Ala cleavable linker	[55]
ADC Info	ADCT-212	Undisclosed	KLK3	SG2000	Vali-Ala cleavable linker	[56]
ADC Info	AF-GPL	Anti-ody fragment (AF)	EGFR; ERBB3	Gemcitabine and paclitaxel loaded liposome	Undisclosed	[57]
ADC Info	Alemtuzumab-Compound 43	Alemtuzumab	CD52	PBD dimer	Alemtuzumab-Compound 43 linker	[53]
ADC Info	Alemtuzumab-Compound 49	Alemtuzumab	CD52	PBD dimer	Alemtuzumab-Compound 49 linker	[53]
ADC Info	Alemtuzumab-Compound 74	Alemtuzumab	CD52	PBD dimer	Alemtuzumab-Compound 74 linker	[53]
ADC Info	Alpha-CD22-HC-A140C-10	Anti-CD22-HC-A140C	CD22	seco-CBI-dimer	Mc-peptidomimetic based linker 10	[58]
ADC Info	Alpha-CD22-HC-A140C-11	Anti-CD22-HC-A140C	CD22	seco-CBI-dimer	Mc-PEG2	[58]
ADC Info	Alpha-CD22-LC-K149C-10	Anti-CD22-LC-K149C	CD22	seco-CBI-dimer	Mc-peptidomimetic based linker 10	[58]
ADC Info	Alpha-CD22-LC-K149C-11	Anti-CD22-LC-K149C	CD22	seco-CBI-dimer	Mal-PEG2	[58]
ADC Info	Alpha-CD22-LC-K149C-12	Anti-CD22-LC-K149C	CD22	Seco-CBI-dimer 12	Mc-peptidomimetic based linker 12	[58]
ADC Info	Alpha-CD22-LC-V205C-10	Anti-CD22-LC-V205C	CD22	seco-CBI-dimer	Mc-peptidomimetic based linker 10	[58]
ADC Info	Alpha-gD-LC-K149C-10	Anti-gD-LC-K149C	LY6E	seco-CBI-dimer	Mc-peptidomimetic based linker 10	[58]
ADC Info	Alpha-gD-LC-K149C-12	Anti-gD-LC-K149C	Gd	Seco-CBI-dimer 12	Mc-peptidomimetic based linker 12	[58]
ADC Info	Alpha-HER2-Duo 405	Anti-HER2 mAb	ERBB2	Duocarmycin 405	Undisclosed	[59]
ADC Info	Alpha-Ly6E-LC-K149C-10	Anti-Ly6E-LC-K149C	Gd	seco-CBI-dimer	Mc-peptidomimetic based linker 10	[58]
ADC Info	Alpha-Ly6E-LC-K149C-11	Anti-Ly6E-LC-K149C	LY6E	seco-CBI-dimer	Mal-PEG2	[58]
ADC Info	Alpha-NaPi2b-LC-K149C-10	Anti-NaPi2b-LC-K149C	SLC34A2	seco-CBI-dimer	Mc-peptidomimetic based linker 10	[58]
ADC Info	Alpha-NaPi2b-LC-K149C-11	Anti-NaPi2b-LC-K149C	SLC34A2	seco-CBI-dimer	Mal-PEG2	[58]
ADC Info	Amatuximab-Compound 43	Amatuximab	MSLN	PBD dimer	Amatuximab-Compound 43 linker	[53]
ADC Info	Amatuximab-Compound 49	Amatuximab	MSLN	PBD dimer	Amatuximab-Compound 49 linker	[53]
ADC Info	Amatuximab-Compound 74	Amatuximab	MSLN	PBD dimer	Amatuximab-Compound 74 linker	[53]
ADC Info	Anti-ApoD PBD	Anti-ApoD Anti-ody	APOD	PBD dimer	Undisclosed	[60]
ADC Info	Anti-B4 monoclonal antibody-DC1 conjugate	Undisclosed	CD19	DC1	Undisclosed	[61]
ADC Info	Anti-BCMA 15B2GL-SG3249	Anti-BCMA antibody 15B2GL	TNFRSF17	SG3199	CL2A	[62]
ADC Info	Anti-BCMA 15B2WT-SG3249	Anti-BCMA antibody 15B2WT	TNFRSF17	SG3199	CL2A	[62]
ADC Info	Anti-BCMA I09-SG3249	Anti-BCMA antibody I09	TNFRSF17	SG3199	CL2A	[62]
ADC Info	Anti-BCMA J6M0-SG3249	Anti-BCMA antibody J6M0	TNFRSF17	SG3199	CL2A	[62]
ADC Info	Anti-BCMA L15-SG3249	Anti-BCMA antibody L15	TNFRSF17	SG3199	CL2A	[62]
ADC Info	Anti-BCMA M02-SG3249	Anti-BCMA antibody M02	TNFRSF17	SG3199	CL2A	[62]
ADC Info	Anti-BCMA N22-SG3249	Anti-BCMA antibody N22	TNFRSF17	SG3199	CL2A	[62]
ADC Info	Anti-BCMA P10-SG3249	Anti-BCMA antibody P10	TNFRSF17	SG3199	CL2A	[62]
ADC Info	Anti-BCMA R347-SG3249	Anti-BCMA antibody R347	TNFRSF17	SG3199	CL2A	[62]
ADC Info	Anti-CD22- (LC:K149C)-SN36248	Pinatuzumab	CD22	seco-CBI-dimer	Mal-PEG2	[63]
ADC Info	Anti-CD22-SN36248	Anti-CD22 10F4 Thiomab (LC:K149C)	CD22	seco-CBI-dimer	Mal-PEG2	[63]
ADC Info	Anti-CD30-LDM	Recombinant human CD30Fc fusion protein	TNFRSF8	Lidamycin	Uncleavable linker	[64]
ADC Info	Anti-CD59 mAb-Compound 43	Anti-CD59 mAb	CD59	PBD dimer	Anti-CD59 mAb-Compound 43 linker	[53]
ADC Info	Anti-CD59 mAb-Compound 49	Anti-CD59 mAb	CD59	PBD dimer	Anti-CD59 mAb-Compound 49 linker	[53]
ADC Info	Anti-CD59 mAb-Compound 74	Anti-CD59 mAb	CD59	PBD dimer	Anti-CD59 mAb-Compound 74 linker	[53]
ADC Info	Anti-CD70-45 ADC	Anti-CD70 mAb	CD70	Tetrahydroisoquinoline-based PBD dimer 17	Mc-Val-Cit-PABC	[65]
ADC Info	Anti-CLL-1-ds-PBD	Anti-CLL-1 THIOMAB Anti-ody	CLEC12A	SG2000	Undisclosed	[66]
ADC Info	Anti-c-Met IgG-OXA	Anti-MET mAb	MET	Oxaliplatin	Dipeptide-p-amidobenzyl alcohol linker	[67]
ADC Info	Anti-EGFR-Ala-Ala-IGN	Anti-EGFR mAb	EGFR	Indolinobenzodiazepine dimer	Ala-Ala dipeptide	[68]
ADC Info	Anti-EGFR-Val-Gln-IGN	Anti-EGFR mAb	EGFR	Indolinobenzodiazepine dimer	Val-Gln dipeptide linker	[68]
ADC Info	Anti-FOLR1-Ala-Ala-IGN	Anti-FOLR1 mAb	FOLR1	Indolinobenzodiazepine dimer	Ala-Ala dipeptide	[68]
ADC Info	Anti-FOLR1-Val-Gln-IGN	Anti-FOLR1 mAb	FOLR1	Indolinobenzodiazepine dimer	Val-Gln dipeptide linker	[68]
ADC Info	Anti-FucGM1-45 ADC	Anti-FucGM1 mAb	Undisclosed	Tetrahydroisoquinoline-based PBD dimer 17	Mc-Val-Cit-PABC	[65]
ADC Info	Anti-FucGM1-46 ADC	Anti-FucGM1 mAb	Undisclosed	Tetrahydroisoquinoline-based PBD dimer 17	PEG2-Val-Cit-PABC	[65]
ADC Info	Anti-FucGM1-47 ADC	Anti-FucGM1 mAb	Undisclosed	Tetrahydroisoquinoline-based PBD dimer 17	PEG4-Val-Cit-PABC	[65]
ADC Info	Anti-FucGM1-48 ADC	Anti-FucGM1 mAb	Undisclosed	Tetrahydroisoquinoline-based PBD dimer 17	PEG8-Val-Cit-PABC	[65]
ADC Info	Anti-HER2 mAb-Compound 43	Anti-HER2 mAb	ERBB2	PBD dimer	Anti-HER2 mAb-Compound 43 linker	[53]
ADC Info	Anti-HER2 mAb-Compound 49	Anti-HER2 mAb	ERBB2	PBD dimer	Anti-HER2 mAb-Compound 49 linker	[53]
ADC Info	Anti-HER2 mAb-Compound 74	Anti-HER2 mAb	ERBB2	PBD dimer	Anti-HER2 mAb-Compound 74 linker	[53]
ADC Info	Anti-ICOS-PBD	Murine Anti-ICOS Anti-ody	ICOS	PBD dimer	Undisclosed	[69]
ADC Info	Anti-IL13RA2 PBD ADC	Anti-IL13RA2 mAb 2E10	IL13RA2	SGD-1882	Mc-Val-Ala	[70]
ADC Info	Anti-MSL1 mAb-Compound 43	Anti-MSL1 mAb	MSL1	PBD dimer	Anti-MSL1 mAb-Compound 43 linker	[53]
ADC Info	Anti-MSL1 mAb-Compound 49	Anti-MSL1 mAb	MSL1	PBD dimer	Anti-MSL1 mAb-Compound 49 linker	[53]
ADC Info	Anti-MSL1 mAb-Compound 74	Anti-MSL1 mAb	MSL1	PBD dimer	Anti-MSL1 mAb-Compound 74 linker	[53]
ADC Info	Anti-MSLN-44 ADC	Anti-MSLN mAb	MSLN	Tetrahydroisoquinoline-based PBD dimer 14	Mal-PEG8-Val-Cit-PABC	[65]
ADC Info	Anti-MSLN-45 ADC	Anti-MSLN mAb	MSLN	Tetrahydroisoquinoline-based PBD dimer 17	Mc-Val-Cit-PABC	[65]
ADC Info	Anti-MSLN-46 ADC	Anti-MSLN mAb	MSLN	Tetrahydroisoquinoline-based PBD dimer 17	PEG2-Val-Cit-PABC	[65]
ADC Info	Anti-MSLN-47 ADC	Anti-MSLN mAb	MSLN	Tetrahydroisoquinoline-based PBD dimer 17	PEG4-Val-Cit-PABC	[65]
ADC Info	Anti-MSLN-48 ADC	Anti-MSLN mAb	MSLN	Tetrahydroisoquinoline-based PBD dimer 17	PEG8-Val-Cit-PABC	[65]
ADC Info	Anti-PDGFRB cotinine scFv-C-scFv-duocarmycin	Bispecific Anti-PDGFRB + cotinine scFv-C-scFv fusion protein	PDGFRB	DEAEA duocarmycin	PEG3-Val-Cit-PABC	[71]
ADC Info	Anti-PDGFRB C-scFv Duocarmycin	Anti-mouse PDGFRB Anti-ody	PDGFRB	Duocarmycin A	Undisclosed	[71]
ADC Info	B12-SG3249	B12	env	SG3199	Mal-PEG8-Val-Ala-PABC	[72]
ADC Info	B2M-duocarmycin ADC	LS-B2200	B2M	Duocarmycin A	Bis-Tolylsulfonyl-Propanoyl-Benzamide-Glu-NH-PEG(24u)-OMe-Val-Cit-PAB	[73]
ADC Info	B4-SMCC-DC4	Anti-CD19 mAb B4	CD19	Phosphate prodrugs 40 (DC4)	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[74]
ADC Info	B4-SPP-DC1	Anti-CD19 mAb B4	CD19	DC1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[74]
ADC Info	B4-SPP-DC4	Anti-CD19 mAb B4	CD19	Phosphate prodrugs 40 (DC4)	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[74]
ADC Info	B4-SPP-DC44	Anti-CD19 mAb B4	CD19	DC44	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[74]
ADC Info	Bevacizumab-Compound 43	Bevacizumab	VEGFA	PBD dimer	Bevacizumab-Compound 43 linker	[53]
ADC Info	Bevacizumab-Compound 49	Bevacizumab	VEGFA	PBD dimer	Bevacizumab-Compound 49 linker	[53]
ADC Info	Bevacizumab-Compound 74	Bevacizumab	VEGFA	PBD dimer	Bevacizumab-Compound 74 linker	[53]
ADC Info	Blinatumomab-Compound 43	Blinatumomab	CD19; CD3D	PBD dimer	Blinatumomab-Compound 43 linker	[53]
ADC Info	Blinatumomab-Compound 49	Blinatumomab	CD19; CD3D	PBD dimer	Blinatumomab-Compound 49 linker	[53]
ADC Info	Blinatumomab-Compound 74	Blinatumomab	CD19; CD3D	PBD dimer	Blinatumomab-Compound 74 linker	[53]
ADC Info	Brentuximab-Compound 43	Brentuximab	TNFRSF8	PBD dimer	Brentuximab-Compound 43 linker	[53]
ADC Info	Brentuximab-Compound 49	Brentuximab	TNFRSF8	PBD dimer	Brentuximab-Compound 49 linker	[53]
ADC Info	Brentuximab-Compound 74	Brentuximab	TNFRSF8	PBD dimer	Brentuximab-Compound 74 linker	[53]
ADC Info	CD123-CPI ADC (Pfizer)	Undisclosed	IL3RA	Cyclopropylpyrroloindoline (CPI) payload	Undisclosed	[75]
ADC Info	CD25-ADC	Anti-CD25 mAb PC61	ISG20	SG3199	Mal-PEG8-Val-Ala-PABC	[76]
ADC Info	CD33-CPI dimer ADC	Anti-CD33 Anti-ody 11A1	CD33	Bicyclopentyl-seco-CBI-dimer	AcLys-Val-Cit-PABC-DMAE	[77]
ADC Info	CDX-0125-TEI	Anti-ALK mAb DX-0125	ALK	NMS-P945	Undisclosed	[78]
ADC Info	Cetuximab- (FGX16-11)	Cetuximab	EGFR	FGX8-46	Mc-Val-Ala-PABC	[79]
ADC Info	Cetuximab-Compound 43	Cetuximab	EGFR	PBD dimer	Cetuximab-Compound 43 linker	[53]
ADC Info	Cetuximab-Compound 49	Cetuximab	EGFR	PBD dimer	Cetuximab-Compound 49 linker	[53]
ADC Info	Cetuximab-Compound 74	Cetuximab	EGFR	PBD dimer	Cetuximab-Compound 74 linker	[53]
ADC Info	Cetuximab-DNA conjugate	Cetuximab	EGFR	DNA mimics	Undisclosed	[80]
ADC Info	chDAB4-SG3249	Chimeric DAB4 (chDAB4)	SSB	SG3199	Mal-PEG8-Val-Ala-PABC	[72]
ADC Info	CIRCR201-dPBD	Anti-MET mAb cIRCR201	MET	Glucuronide-dPBD	Iso-PEG5-beta-glucuronide	[81]
ADC Info	CLL1-ADC	Fully humanized Anti-CLL1 mAb	CLEC12A	D211	Mal-PEG8-Val-Cit-PABC	[82]
ADC Info	Cotinine-duocarmycin	ERC6 bispecific Anti-ody (fuse Anti-cotinine scFv to cetuximab CH3 domain)	EGFR	Duocarmycin Sa	Mc-Val-Cit-PABC-DMAE	[71]
ADC Info	CyEt-Pan-Duo	Panitumumab	EGFR	DEAEA duocarmycin	Mal-PEG4-Triazol-Cyanine cage	[83]
ADC Info	D2B-DCM	Anti-PSMA mAb D2B	FOLH1	Duocarmycin A	Mc-Val-Cit-PABC	[84]
ADC Info	D3-GPC2-PBD	Fully human D3-GPC2-IgG1	GPC2	PBD dimer	Undisclosed	[85]
ADC Info	DAB4-DuoDM	DAB4	SSB	DEAEA duocarmycin	Mal-PEG4-Val-Cit-PABC	[72]
ADC Info	Dualtargeting lidamycin ADC	Undisclosed	EGFR; ERBB2	Lidamycin	Undisclosed	[86]
ADC Info	EGFR-ADC 13a	Anti-EGFR mAb	EGFR	PBD dimer 14a	Adipic acid-Val-Ala-PABC	[87]
ADC Info	EGFR-ADC 13b	Anti-EGFR mAb	EGFR	PBD dimer 14b	Adipic acid-Val-Ala-PABC	[87]
ADC Info	EGFR-ADC 13c	Anti-EGFR mAb	EGFR	PBD dimer 14c	Adipic acid-Val-Ala-PABC	[87]
ADC Info	ENDOS/ADC	Anti-CD248 mAb hMP-E-8.3	CD248	Duocarmycin derivative	Val-Cit	[88]
ADC Info	Engineered HER-SG3227	Engineered trastuzumab	ERBB2	SG2219	Acetamide-PEG4-Val-Ala-PABA	[89]
ADC Info	EV20/NMS-P945	EV20	ERBB3	NMS-P528	Cathepsin-cleavable peptidic linker with self-immolating spacer	[90]
ADC Info	FOLR1-ADC 13a	Anti-FOLR1 mAb	FOLR1	PBD dimer 13a	Adipic acid-Val-Ala-PABC	[87]
ADC Info	FOLR1-ADC 13b	Anti-FOLR1 mAb	FOLR1	PBD dimer 13b	Adipic acid-Val-Ala-PABC	[87]
ADC Info	FOLR1-ADC 13c	Anti-FOLR1 mAb	FOLR1	PBD dimer 13c	Adipic acid-Val-Ala-PABC	[87]
ADC Info	FOLR1-ADC 15	Anti-FOLR1 mAb	FOLR1	PBD dimer 13c	Adipic acid-Val-CIt-PABC	[87]
ADC Info	Fv-LDP-D3-AE	Fv-LDP-D3	EGFR	Lidamycin	Undisclosed	[91]
ADC Info	Gemtuzumab-Compound 43	Gemtuzumab	CD33	PBD dimer	Gemtuzumab-Compound 43 linker	[53]
ADC Info	Gemtuzumab-Compound 49	Gemtuzumab	CD33	PBD dimer	Gemtuzumab-Compound 49 linker	[53]
ADC Info	Gemtuzumab-Compound 74	Gemtuzumab	CD33	PBD dimer	Gemtuzumab-Compound 74 linker	[53]
ADC Info	GFRA1 targeted antibody-drug conjugate	Anti-GFRA1 mAb	GFRA1	SG3199	Mal-PEG8-Val-Ala-PABC	[92]
ADC Info	Golimumab-Compound 43	Golimumab	TNF	PBD dimer	Golimumab-Compound 43 linker	[53]
ADC Info	Golimumab-Compound 49	Golimumab	TNF	PBD dimer	Golimumab-Compound 49 linker	[53]
ADC Info	Golimumab-Compound 74	Golimumab	TNF	PBD dimer	Golimumab-Compound 74 linker	[53]
ADC Info	GPR56-ADC	Anti-GPR56 Anti-ody 10C7	ADGRG1	Duocarmycin Sa	Mal-Val-Cit-PABC-DMEA-PEG2	[93]
ADC Info	HD12-SG3227	Anti-MET mAb hD12	MET	PBD dimer SG3227	Mal-PEG8-Val-Ala-PABC	[94]
ADC Info	HD12-SG3246	Anti-MET mAb hD12	MET	PBD dimer SG3246	Mal-PEG8-Val-Ala-PABC	[94]
ADC Info	HD12-SG3249	Anti-MET mAb hD12	MET	PBD dimer SG3249	Mal-PEG8-Val-Ala-PABC	[94]
ADC Info	HD12-SG3259	Anti-MET mAb hD12	MET	PBD dimer SG3259	Mal-PEG8-Val-Ala-PABC	[94]
ADC Info	HD12-SG3315	Anti-MET mAb hD12	MET	PBD dimer SG3315	Mal-PEG8-Val-Ala-PABC	[94]
ADC Info	HER2-HC-H-SS-PBD	Anti-HER2 mAb	ERBB2	SG2000	H-disulfide linker	[95]
ADC Info	HER2-HC-Me-SS-PBD	Anti-HER2 mAb	ERBB2	SG2000	Me-disulfide linker	[95]
ADC Info	HER2-LC-H-SS-PBD	Anti-HER2 mAb	ERBB2	SG2000	H-disulfide linker	[95]
ADC Info	HER2-LC-Me-SS-PBD	Anti-HER2 mAb	ERBB2	SG2000	Me-disulfide linker	[95]
ADC Info	HER-SG3249	Trastuzumab	ERBB2	SG3199	Mal-PEG8-Val-Ala-PABC	[96]
ADC Info	HLL2-PBD	Epratuzumab	CD22	SG3199	Mal-PEG8-Val-Ala-PABC	[97]
ADC Info	hmAb-C-DUBA	hmAb-C	CD276	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[98]
ADC Info	HuAD208.4.1-PBD-DAR2	huAD208.4.1	LRRC15	PBD dimer	Mc-Val-Ala	[99]
ADC Info	HuB4-DGN462	Undisclosed	CD19	DGN462	Sulfo-SPDB	[100]
ADC Info	HuC242-SMCC-DC4	Cantuzumab	SDC1	Phosphate prodrugs 40 (DC4)	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[74]
ADC Info	HuC242-SPDB-DC4	Cantuzumab	SDC1	Phosphate prodrugs 40 (DC4)	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[74]
ADC Info	HuC242-SPP-DC4	Cantuzumab	SDC1	Phosphate prodrugs 40 (DC4)	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[74]
ADC Info	HuM25-S239C-PBD-E2	huM25-S239C	LRRC15	PBD dimer	Mc-Val-Ala	[99]
ADC Info	HuN901-CC-1065	Lorvotuzumab	NCAM1	Rachelmycin	Cleavable disulfide	[101]
ADC Info	HYP7-DC	Humanized GPC3-specific Anti-ody YP7	GPC3	Duocarmycin Sa	Mal-PEG4-Val-Cit-PABC-DMAE	[102]
ADC Info	Ibritumomab-Compound 43	Ibritumomab	MS4A1	PBD dimer	Ibritumomab-Compound 43 linker	[53]
ADC Info	Ibritumomab-Compound 49	Ibritumomab	MS4A1	PBD dimer	Ibritumomab-Compound 49 linker	[53]
ADC Info	Ibritumomab-Compound 74	Ibritumomab	MS4A1	PBD dimer	Ibritumomab-Compound 74 linker	[53]
ADC Info	IKS-01	Isumab01	FOLR1	FGX2-62	Undisclosed	[103]
ADC Info	Infliximab-Compound 43	Infliximab	TNF	PBD dimer	Infliximab-Compound 43 linker	[53]
ADC Info	Infliximab-Compound 49	Infliximab	TNF	PBD dimer	Infliximab-Compound 49 linker	[53]
ADC Info	Infliximab-Compound 74	Infliximab	TNF	PBD dimer	Infliximab-Compound 74 linker	[53]
ADC Info	IPH43	Glycosylated Anti-MICA Anti-ody	MICA	PBD dimer	Undisclosed	[104]
ADC Info	Ipilimumab-Compound 43	Ipilimumab	CTLA4	PBD dimer	Ipilimumab-Compound 43 linker	[53]
ADC Info	Ipilimumab-Compound 49	Ipilimumab	CTLA4	PBD dimer	Ipilimumab-Compound 49 linker	[53]
ADC Info	Ipilimumab-Compound 74	Ipilimumab	CTLA4	PBD dimer	Ipilimumab-Compound 74 linker	[53]
ADC Info	KTN0182A	Undisclosed	KIT	PBD dimer	Undisclosed	[105]
ADC Info	LA22-MMC	Anti-EGFR mAb LA22	EGFR	Mitomycin C	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[106]
ADC Info	M276-SL-PBD	Anti-CD276 mAb m276-SL	CD276	PBD dimer	Mc-Val-Ala	[107]
ADC Info	Masked ADC (Adagene/ADC Therapeutics)	Undisclosed	Undisclosed	PBD dimer	Undisclosed	[108]
ADC Info	MEDI-0641	5T4_0108	TPBG	5T4-PBD	Mal-PEG8-Val-Ala-PABC	[109]
ADC Info	Monoclonal antibody A5B7-cisplatin conjugate	Anti-CEACAM5 mAb A5B7	PSG2	Cisplatin	Undisclosed	[110]
ADC Info	MUC16-Mc-Val-Cit-PABC-CBI dimer	Thio hu Anti-MUC16	MUC16	seco-CBI-dimer	Mc-Val-Cit-PABC	[111]
ADC Info	Nimotuzumab-Compound 43	Nimotuzumab	EGFR	PBD dimer	Nimotuzumab-Compound 43 linker	[53]
ADC Info	Nimotuzumab-Compound 49	Nimotuzumab	EGFR	PBD dimer	Nimotuzumab-Compound 49 linker	[53]
ADC Info	Nimotuzumab-Compound 74	Nimotuzumab	EGFR	PBD dimer	Nimotuzumab-Compound 74 linker	[53]
ADC Info	NV105	Undisclosed	CD276	Temozolomide	Undisclosed	[112]
ADC Info	Ofatumumab-Compound 43	Ofatumumab	MS4A1	PBD dimer	Ofatumumab-Compound 43 linker	[53]
ADC Info	Ofatumumab-Compound 49	Ofatumumab	MS4A1	PBD dimer	Ofatumumab-Compound 49 linker	[53]
ADC Info	Ofatumumab-Compound 74	Ofatumumab	MS4A1	PBD dimer	Ofatumumab-Compound 74 linker	[53]
ADC Info	OHPAS ADC-2	Trastuzumab	ERBB2	SG2000	Ortho-hydroxy-protected aryl sulfate	[113]
ADC Info	OHPAS ADC-3	Trastuzumab	ERBB2	seco-CBI-indole	Ortho-hydroxy-protected aryl sulfate	[113]
ADC Info	OHPAS ADC-4	Trastuzumab	ERBB2	CBI-dimer-beta-Gal	Ortho-hydroxy-protected aryl sulfate	[113]
ADC Info	Panitumumab-Compound 43	Panitumumab	EGFR	PBD dimer	Panitumumab-Compound 43 linker	[53]
ADC Info	Panitumumab-Compound 49	Panitumumab	EGFR	PBD dimer	Panitumumab-Compound 49 linker	[53]
ADC Info	Panitumumab-Compound 74	Panitumumab	EGFR	PBD dimer	Panitumumab-Compound 74 linker	[53]
ADC Info	Panitumumab-DNA conjugate	Panitumumab	EGFR	DNA mimics	Undisclosed	[80]
ADC Info	PCM5B14-DCM	H5B14	MST1R	Duocarmycin Sa	Mc-PEG4-Val-Cit-PABC-DMAE	[114]
ADC Info	Pertuzumab-Compound 43	Pertuzumab	ERBB2	PBD dimer	Pertuzumab-Compound 43 linker	[53]
ADC Info	Pertuzumab-Compound 49	Pertuzumab	ERBB2	PBD dimer	Pertuzumab-Compound 49 linker	[53]
ADC Info	Pertuzumab-Compound 74	Pertuzumab	ERBB2	PBD dimer	Pertuzumab-Compound 74 linker	[53]
ADC Info	PF-06888667	Trastuzumab	ERBB2	SW-163D	AcLys-Val-Cit-PABC-DMAE	[115]
ADC Info	Promiximab-DUBA	Promiximab	NCAM1	seco-DUBA	Mal-Val-Cit-PABA-Cyclization spacer	[116]
ADC Info	PYX-203	Undisclosed	IL3RA	Cyclopropylpyrroloindole (CPI) DNA-damaging payload	Lysosomal cleavable linker	[117]
ADC Info	RC58-ADC-1	RC58	CD19	Dumycin-7	Bis-bromine linker-PEG4-Asn-Ala-ethylenediamine	[118]
ADC Info	Recombinant humanized anti-EGFR mAb-DUO-5 conjugate	Undisclosed	EGFR	Duostatin 5	Undisclosed	[119]
ADC Info	REGN-3124-PBD	REGN3124	EGFRvIII	SG3199	Mal-PEG8-Val-Ala-PABC	[120]
ADC Info	Rituximab-Compound 43	Rituximab	MS4A1	PBD dimer	Rituximab-Compound 43 linker	[53]
ADC Info	Rituximab-Compound 49	Rituximab	MS4A1	PBD dimer	Rituximab-Compound 49 linker	[53]
ADC Info	Rituximab-Compound 74	Rituximab	MS4A1	PBD dimer	Rituximab-Compound 74 linker	[53]
ADC Info	Rituximab-DNA conjugate	Rituximab	MS4A1	DNA mimics	Undisclosed	[80]
ADC Info	Sacituzumab-Compound 43	Sacituzumab	TACSTD2	PBD dimer	Sacituzumab-Compound 43 linker	[53]
ADC Info	Sacituzumab-Compound 49	Sacituzumab	TACSTD2	PBD dimer	Sacituzumab-Compound 49 linker	[53]
ADC Info	Sacituzumab-Compound 74	Sacituzumab	TACSTD2	PBD dimer	Sacituzumab-Compound 74 linker	[53]
ADC Info	Sal5-DuoDM	Sal5	EGFR; ERBB3	DEAEA duocarmycin	Mal-PEG4-Val-Cit-PABC	[72]
ADC Info	SC16.101-DL2	SC16.101	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.101-DL3	SC16.101	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.101-DL4	SC16.101	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.101-DL5	SC16.101	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.103-DL2	SC16.103	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.103-DL3	SC16.103	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.103-DL4	SC16.103	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.103-DL5	SC16.103	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.104-DL2	SC16.104	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.104-DL3	SC16.104	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.104-DL4	SC16.104	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.104-DL5	SC16.104	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.105-DL2	SC16.105	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.105-DL3	SC16.105	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.105-DL4	SC16.105	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.105-DL5	SC16.105	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.106-DL2	SC16.106	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.106-DL3	SC16.106	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.106-DL4	SC16.106	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.106-DL5	SC16.106	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.107-DL2	SC16.107	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.107-DL3	SC16.107	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.107-DL4	SC16.107	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.107-DL5	SC16.107	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.108-DL2	SC16.108	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.108-DL3	SC16.108	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.108-DL4	SC16.108	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.108-DL5	SC16.108	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.109-DL2	SC16.109	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.109-DL3	SC16.109	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.109-DL4	SC16.109	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.109-DL5	SC16.109	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.10-DL2	SC16.10	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.10-DL3	SC16.10	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.10-DL4	SC16.10	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.10-DL5	SC16.10	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.110-DL2	SC16.110	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.110-DL3	SC16.110	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.110-DL4	SC16.110	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.110-DL5	SC16.110	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.111-DL2	SC16.111	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.111-DL3	SC16.111	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.111-DL4	SC16.111	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.111-DL5	SC16.111	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.113-DL2	SC16.113	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.113-DL3	SC16.113	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.113-DL4	SC16.113	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.113-DL5	SC16.113	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.114-DL2	SC16.114	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.114-DL3	SC16.114	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.114-DL4	SC16.114	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.114-DL5	SC16.114	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.115-DL2	SC16.115	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.115-DL3	SC16.115	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.115-DL4	SC16.115	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.115-DL5	SC16.115	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.116-DL2	SC16.116	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.116-DL3	SC16.116	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.116-DL4	SC16.116	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.116-DL5	SC16.116	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.117-DL2	SC16.117	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.117-DL3	SC16.117	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.117-DL4	SC16.117	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.117-DL5	SC16.117	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.118-DL2	SC16.118	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.118-DL3	SC16.118	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.118-DL4	SC16.118	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.118-DL5	SC16.118	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.11-DL2	SC16.11	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.11-DL3	SC16.11	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.11-DL4	SC16.11	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.11-DL5	SC16.11	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.120-DL2	SC16.120	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.120-DL3	SC16.120	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.120-DL4	SC16.120	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.120-DL5	SC16.120	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.121-DL2	SC16.121	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.121-DL3	SC16.121	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.121-DL4	SC16.121	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.121-DL5	SC16.121	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.122-DL2	SC16.122	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.122-DL3	SC16.122	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.122-DL4	SC16.122	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.122-DL5	SC16.122	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.123-DL2	SC16.123	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.123-DL3	SC16.123	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.123-DL4	SC16.123	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.123-DL5	SC16.123	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.124-DL2	SC16.124	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.124-DL3	SC16.124	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.124-DL4	SC16.124	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.124-DL5	SC16.124	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.125-DL2	SC16.125	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.125-DL3	SC16.125	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.125-DL4	SC16.125	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.125-DL5	SC16.125	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.126-DL2	SC16.126	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.126-DL3	SC16.126	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.126-DL4	SC16.126	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.126-DL5	SC16.126	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.129-DL2	SC16.129	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.129-DL3	SC16.129	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.129-DL4	SC16.129	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.129-DL5	SC16.129	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.130-DL2	SC16.130	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.130-DL3	SC16.130	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.130-DL4	SC16.130	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.130-DL5	SC16.130	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.131-DL2	SC16.131	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.131-DL3	SC16.131	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.131-DL4	SC16.131	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.131-DL5	SC16.131	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.132-DL2	SC16.132	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.132-DL3	SC16.132	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.132-DL4	SC16.132	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.132-DL5	SC16.132	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.133-DL2	SC16.133	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.133-DL3	SC16.133	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.133-DL4	SC16.133	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.133-DL5	SC16.133	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.134-DL2	SC16.134	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.134-DL3	SC16.134	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.134-DL4	SC16.134	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.134-DL5	SC16.134	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.135-DL2	SC16.135	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.135-DL3	SC16.135	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.135-DL4	SC16.135	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.135-DL5	SC16.135	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.136-DL2	SC16.136	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.136-DL3	SC16.136	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.136-DL4	SC16.136	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.136-DL5	SC16.136	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.137-DL2	SC16.137	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.137-DL3	SC16.137	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.137-DL4	SC16.137	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.137-DL5	SC16.137	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.138-DL2	SC16.138	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.138-DL3	SC16.138	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.138-DL4	SC16.138	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.138-DL5	SC16.138	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.139-DL2	SC16.139	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.139-DL3	SC16.139	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.139-DL4	SC16.139	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.139-DL5	SC16.139	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.13-DL2	SC16.13	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.13-DL3	SC16.13	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.13-DL4	SC16.13	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.13-DL5	SC16.13	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.140-DL2	SC16.140	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.140-DL3	SC16.140	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.140-DL4	SC16.140	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.140-DL5	SC16.140	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.141-DL2	SC16.141	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.141-DL3	SC16.141	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.141-DL4	SC16.141	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.141-DL5	SC16.141	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.142-DL2	SC16.142	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.142-DL3	SC16.142	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.142-DL4	SC16.142	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.142-DL5	SC16.142	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.143-DL2	SC16.143	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.143-DL3	SC16.143	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.143-DL4	SC16.143	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.143-DL5	SC16.143	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.144-DL2	SC16.144	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.144-DL3	SC16.144	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.144-DL4	SC16.144	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.144-DL5	SC16.144	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.147-DL2	SC16.147	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.147-DL3	SC16.147	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.147-DL4	SC16.147	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.147-DL5	SC16.147	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.148-DL2	SC16.148	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.148-DL3	SC16.148	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.148-DL4	SC16.148	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.148-DL5	SC16.148	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.149-DL2	SC16.149	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.149-DL3	SC16.149	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.149-DL4	SC16.149	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.149-DL5	SC16.149	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.150-DL2	SC16.150	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.150-DL3	SC16.150	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.150-DL4	SC16.150	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.150-DL5	SC16.150	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.15-DL2	SC16.15	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.15-DL3	SC16.15	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.15-DL4	SC16.15	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.15-DL5	SC16.15	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.18-DL2	SC16.18	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.18-DL3	SC16.18	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.18-DL4	SC16.18	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.18-DL5	SC16.18	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.19-DL2	SC16.19	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.19-DL3	SC16.19	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.19-DL4	SC16.19	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.19-DL5	SC16.19	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.20-DL2	SC16.20	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.20-DL3	SC16.20	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.20-DL4	SC16.20	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.20-DL5	SC16.20	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.21-DL2	SC16.21	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.21-DL3	SC16.21	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.21-DL4	SC16.21	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.21-DL5	SC16.21	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.22-DL2	SC16.22	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.22-DL3	SC16.22	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.22-DL4	SC16.22	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.22-DL5	SC16.22	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.23-DL2	SC16.23	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.23-DL3	SC16.23	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.23-DL4	SC16.23	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.23-DL5	SC16.23	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.25-DL2	SC16.25	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.25-DL3	SC16.25	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.25-DL4	SC16.25	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.25-DL5	SC16.25	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.26-DL2	SC16.26	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.26-DL3	SC16.26	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.26-DL4	SC16.26	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.26-DL5	SC16.26	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.29-DL2	SC16.29	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.29-DL3	SC16.29	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.29-DL4	SC16.29	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.29-DL5	SC16.29	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.30-DL2	SC16.30	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.30-DL3	SC16.30	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.30-DL4	SC16.30	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.30-DL5	SC16.30	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.31-DL2	SC16.31	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.31-DL3	SC16.31	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.31-DL4	SC16.31	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.31-DL5	SC16.31	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.34-DL2	SC16.34	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.34-DL3	SC16.34	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.34-DL4	SC16.34	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.34-DL5	SC16.34	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.35-DL2	SC16.35	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.35-DL3	SC16.35	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.35-DL4	SC16.35	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.35-DL5	SC16.35	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.36-DL2	SC16.36	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.36-DL3	SC16.36	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.36-DL4	SC16.36	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.36-DL5	SC16.36	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.38-DL2	SC16.38	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.38-DL3	SC16.38	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.38-DL4	SC16.38	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.38-DL5	SC16.38	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.3-DL2	SC16.3	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.3-DL3	SC16.3	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.3-DL4	SC16.3	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.3-DL5	SC16.3	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.41-DL2	SC16.41	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.41-DL3	SC16.41	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.41-DL4	SC16.41	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.41-DL5	SC16.41	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.42-DL2	SC16.42	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.42-DL3	SC16.42	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.42-DL4	SC16.42	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.42-DL5	SC16.42	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.45-DL2	SC16.45	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.45-DL3	SC16.45	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.45-DL4	SC16.45	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.45-DL5	SC16.45	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.47-DL2	SC16.47	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.47-DL3	SC16.47	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.47-DL4	SC16.47	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.47-DL5	SC16.47	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.49-DL2	SC16.49	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.49-DL3	SC16.49	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.49-DL4	SC16.49	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.49-DL5	SC16.49	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.4-DL2	SC16.4	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.4-DL3	SC16.4	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.4-DL4	SC16.4	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.4-DL5	SC16.4	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.50-DL2	SC16.50	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.50-DL3	SC16.50	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.50-DL4	SC16.50	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.50-DL5	SC16.50	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.52-DL2	SC16.52	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.52-DL3	SC16.52	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.52-DL4	SC16.52	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.52-DL5	SC16.52	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.55-DL2	SC16.55	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.55-DL3	SC16.55	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.55-DL4	SC16.55	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.55-DL5	SC16.55	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.56-DL2	SC16.56	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.56-DL3	SC16.56	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.56-DL4	SC16.56	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.56-DL5	SC16.56	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.57-DL2	SC16.57	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.57-DL3	SC16.57	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.57-DL4	SC16.57	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.57-DL5	SC16.57	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.58-DL2	SC16.58	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.58-DL3	SC16.58	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.58-DL4	SC16.58	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.58-DL5	SC16.58	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.5-DL2	SC16.5	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.5-DL3	SC16.5	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.5-DL4	SC16.5	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.5-DL5	SC16.5	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.61-DL2	SC16.61	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.61-DL3	SC16.61	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.61-DL4	SC16.61	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.61-DL5	SC16.61	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.62-DL2	SC16.62	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.62-DL3	SC16.62	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.62-DL4	SC16.62	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.62-DL5	SC16.62	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.63-DL2	SC16.63	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.63-DL3	SC16.63	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.63-DL4	SC16.63	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.63-DL5	SC16.63	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.65-DL2	SC16.65	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.65-DL3	SC16.65	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.65-DL4	SC16.65	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.65-DL5	SC16.65	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.67-DL2	SC16.67	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.67-DL3	SC16.67	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.67-DL4	SC16.67	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.67-DL5	SC16.67	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.68-DL2	SC16.68	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.68-DL3	SC16.68	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.68-DL4	SC16.68	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.68-DL5	SC16.68	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.72-DL2	SC16.72	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.72-DL3	SC16.72	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.72-DL4	SC16.72	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.72-DL5	SC16.72	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.73-DL2	SC16.73	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.73-DL3	SC16.73	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.73-DL4	SC16.73	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.73-DL5	SC16.73	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.78-DL2	SC16.78	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.78-DL3	SC16.78	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.78-DL4	SC16.78	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.78-DL5	SC16.78	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.79-DL2	SC16.79	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.79-DL3	SC16.79	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.79-DL4	SC16.79	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.79-DL5	SC16.79	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.7-DL2	SC16.7	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.7-DL3	SC16.7	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.7-DL4	SC16.7	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.7-DL5	SC16.7	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.80-DL2	SC16.80	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.80-DL3	SC16.80	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.80-DL4	SC16.80	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.80-DL5	SC16.80	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.81-DL2	SC16.81	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.81-DL3	SC16.81	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.81-DL4	SC16.81	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.81-DL5	SC16.81	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.84-DL2	SC16.84	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.84-DL3	SC16.84	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.84-DL4	SC16.84	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.84-DL5	SC16.84	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.88-DL2	SC16.88	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.88-DL3	SC16.88	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.88-DL4	SC16.88	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.88-DL5	SC16.88	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	SC16.8-DL2	SC16.8	DLL3	SG3312	Mc-Val-Ala	[121]
ADC Info	SC16.8-DL3	SC16.8	DLL3	SG2000 derivative PBD 3	Mal-PEG8-Val-Ala	[121]
ADC Info	SC16.8-DL4	SC16.8	DLL3	SG2219	Iodoacetamide-PEG4-Val-Ala-PABC	[121]
ADC Info	SC16.8-DL5	SC16.8	DLL3	SG3199	Mc-PEG8-Val-Ala-PABC	[121]
ADC Info	Site-specific HER-SG3249	Trastuzumab	ERBB2	SG3199	Mal-PEG8-Val-Ala-PABC	[96]
ADC Info	SNS-622-DUO	SNS-622	ASPH	Duocarmycin A	Mc-Val-Cit-PABC	[122]
ADC Info	SYD1035	Anti-PSMA mAb wt HC T120C	FOLH1	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	SYD1091	Anti-PSMA mAb wt HC S41C	FOLH1	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	SYD998	Anti-PSMA mAb wt	FOLH1	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	T1LD1	Anti-IL1RL1 mAb	IL1RL1	N-methyl-uncialamycin	Mal-Val-Cit-PABC	[124]
ADC Info	T1LD2	Anti-IL1RL1 mAb	IL1RL1	N-methyl-uncialamycin	Mal-acetic acid	[124]
ADC Info	T1LD3	Anti-IL1RL1 mAb	IL1RL1	N-methyl-uncialamycin	Mal-PEG8	[124]
ADC Info	T1LD4	Anti-IL1RL1 mAb	IL1RL1	N-methyl-uncialamycin	Mal-glucuronidase cleavable linker	[124]
ADC Info	T1LD5	Anti-IL1RL1 mAb	IL1RL1	N-methyl-uncialamycin	Mal-Val-Cit-glucuronide-PABC	[124]
ADC Info	T1LD6	Anti-IL1RL1 mAb	IL1RL1	N-methyl-uncialamycin	Mal-Val-Cit-gucuronide-PEG8-PABC	[124]
ADC Info	T1LD7	Anti-IL1RL1 mAb	IL1RL1	N-acetyl-gamma-calicheamicin	Mal-Val-Cit-PABC-EDA	[124]
ADC Info	T2LD1	Anti-CD46 mAb	CD46	N-methyl-uncialamycin	Mal-Val-Cit-PABC	[124]
ADC Info	T2LD2	Anti-CD46 mAb	CD46	N-methyl-uncialamycin	Mal-acetic acid	[124]
ADC Info	T2LD3	Anti-CD46 mAb	CD46	N-methyl-uncialamycin	Mal-PEG8	[124]
ADC Info	T2LD4	Anti-CD46 mAb	CD46	N-methyl-uncialamycin	Mal-glucuronidase cleavable linker	[124]
ADC Info	T2LD5	Anti-CD46 mAb	CD46	N-methyl-uncialamycin	Mal-Val-Cit-glucuronide-PABC	[124]
ADC Info	T2LD6	Anti-CD46 mAb	CD46	N-methyl-uncialamycin	Mal-Val-Cit-gucuronide-PEG8-PABC	[124]
ADC Info	Tb074-SG3376	Anti-HpHbR mAb Tb074	Tb06.28F21.220	PBD dimer SG3552	Mal-PEG4	[125]
ADC Info	Tb085-SG3376	Anti-HpHbR mAb Tb085	Tb06.28F21.220	PBD dimer SG3552	Mal-PEG4	[125]
ADC Info	Tositumomab-Compound 43	Tositumomab	MS4A1	PBD dimer	Tositumomab-Compound 43 linker	[53]
ADC Info	Tositumomab-Compound 49	Tositumomab	MS4A1	PBD dimer	Tositumomab-Compound 49 linker	[53]
ADC Info	Tositumomab-Compound 74	Tositumomab	MS4A1	PBD dimer	Tositumomab-Compound 74 linker	[53]
ADC Info	T-PBA	Trastuzumab	ERBB2	PBD-based payload 37b3	Mc-Val-Ala	[126]
ADC Info	Trastuzumab SG-3259	Trastuzumab	ERBB2	SG3312	Mc-Val-Ala	[127]
ADC Info	Trastuzumab-BCN-HydraSpace-Val-Ala-PABC-PBD dimer	Trastuzumab	ERBB2	PBD dimer 2	BCN-HydraSpace-Val-Ala-PABC	[128]
ADC Info	Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-Calicheamicin	Trastuzumab	ERBB2	N-acetyl-gamma-calicheamicin	BCN-HydraSpace-Val-Cit-PABC	[128]
ADC Info	Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-Duocarmycin	Trastuzumab	ERBB2	Duocarmycin Sa	BCN-HydraSpace-Val-Cit-PABC	[128]
ADC Info	Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-Gly-Calicheamicin	Trastuzumab	ERBB2	Gly-calicheamicin	BCN-HydraSpace-Val-Cit-PABC	[128]
ADC Info	Trastuzumab-C239I-SG3249	Trastuzumab	ERBB2	SG3199	Mal-PEG8-Val-Ala-PABC	[129]
ADC Info	Trastuzumab-C239I-SG3400	Engineered trastuzumab	ERBB2	SG3200	Mal-PEG8-Val-Ala-PABC	[130]
ADC Info	Trastuzumab-C239I-SG3600	Engineered trastuzumab	ERBB2	N10-beta-glucuronide SG3200	Mal-PEG8-Val-Ala-PABC	[130]
ADC Info	Trastuzumab-Compound 43	Trastuzumab	ERBB2	PBD dimer	Trastuzumab-Compound 43 linker	[53]
ADC Info	Trastuzumab-Compound 49	Trastuzumab	ERBB2	PBD dimer	Trastuzumab-Compound 49 linker	[53]
ADC Info	Trastuzumab-Compound 74	Trastuzumab	ERBB2	PBD dimer	Trastuzumab-Compound 74 linker	[53]
ADC Info	Trastuzumab-DNA conjugate	Trastuzumab	ERBB2	DNA mimics	Undisclosed	[80]
ADC Info	Trastuzumab-DNA mimic 4	Trastuzumab	ERBB2	Q Pho-DNA mimics	Diphenyltio-Mal-Cap	[131]
ADC Info	Trastuzumab-Flexmab-SG3710	Trastuzumab-Flexmab	ERBB2	SG3199	Mal-PEG8-Val-Ala-PABC	[129]
ADC Info	Trastuzumab-SG3227	Trastuzumab	ERBB2	SG2219	Acetamide-PEG4-Val-Ala-PABA	[89]
ADC Info	Trastuzumab-SG3400 high DAR	Trastuzumab	ERBB2	SG3200	Mal-PEG8-Val-Ala-PABC	[130]
ADC Info	Trastuzumab-SG3600 high DAR	Trastuzumab	ERBB2	N10-beta-glucuronide SG3200	Mal-PEG8-Val-Ala-PABC	[130]
ADC Info	WO2013055987A1 Tmab-101	Trastuzumab	ERBB2	SG2000	WO2013055987A1_Tmab-101 linker	[132]
ADC Info	WO2013055987A1 Tmab-102	Trastuzumab	ERBB2	SG2000	WO2013055987A1_Tmab-102 linker	[132]
ADC Info	WO2013055987A1 Tmab-104	Trastuzumab	ERBB2	SG2000	WO2013055987A1_Tmab-104 linker	[132]
ADC Info	WO2013055987A1 Tmab-110	Trastuzumab	ERBB2	SG2000	WO2013055987A1_Tmab-110 linker	[132]
ADC Info	WO2013055987A1 xCD22-103	Anti-CD22 mAb xCD22	CD22	SG2000	WO2013055987A1_xCD22-103 linker	[132]
ADC Info	WO2015177360A1 ADC-H8-HC40	Anti-5T4 mAb H8 S40C	TPBG	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	WO2015177360A1 ADC-H8-HC41	Anti-5T4 mAb H8 P41C	TPBG	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	WO2015177360A1 ADC-H8-wt	Anti-5T4 mAb H8 wt	TPBG	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	WO2015177360A1 ADC-HC152	Anti-PSMA mAb wt HC E152C	FOLH1	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	WO2015177360A1 ADC-HC153	Anti-PSMA mAb wt HC P153C	FOLH1	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	WO2015177360A1 ADC-HC236	Anti-PSMA mAb wt HC G236C	FOLH1	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	WO2015177360A1 ADC-HC247	Anti-PSMA mAb wt HC P247C	FOLH1	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	WO2015177360A1 ADC-HC339	Anti-PSMA mAb wt HC A339C	FOLH1	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	WO2015177360A1 ADC-HC375	Anti-PSMA mAb wt HC S375C	FOLH1	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	WO2015177360A1 ADC-HC376	Anti-PSMA mAb wt HC D376C	FOLH1	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	WO2015177360A1 ADC-HC41-120	Anti-PSMA mAb wt HC S41C/T120C	FOLH1	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	WO2015177360A1 ADC-HC41-375	Anti-PSMA mAb wt HC S41C/S375C	FOLH1	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	WO2015177360A1 ADC-LC109	Anti-PSMA mAb wt LC T109C	FOLH1	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	WO2015177360A1 ADC-LC154	Anti-PSMA mAb wt LC P40C	FOLH1	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	WO2015177360A1 ADC-LC157	Anti-PSMA mAb wt LC G157C	FOLH1	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	WO2015177360A1 ADC-LC165	Anti-PSMA mAb wt LC L154C	FOLH1	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	WO2015177360A1 ADC-LC205	Anti-PSMA mAb wt LC E165C	FOLH1	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	WO2015177360A1 ADC-LC40	Anti-PSMA mAb wt LC V205C	FOLH1	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	WO2015177360A1 ADC-LC41	Anti-PSMA mAb wt LC G41C	FOLH1	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	WO2015177360A1 ADC-Natalizumab S375C	Natalizumab S375C	ITGA4	seco-DUBA	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer	[123]
ADC Info	WO2021044208A1 ADC 2A2-6	Anti-ROR1 mAb 2A2	ROR1	SG2000	WO2021044208A1_ADC 2A2-6 linker	[47]
ADC Info	WO2021044208A1 ADC 2A2-7	Anti-ROR1 mAb 2A2	ROR1	SG2000	WO2021044208A1_ADC 2A2-7 linker	[47]
ADC Info	WO2021044208A1 ADC A2F2 M1-1	Anti-ROR1 mAb D2B12	ROR1	SG2000	WO2021044208A1_ADC A2F2 M1-1 linker	[47]
ADC Info	WO2021044208A1 ADC A2F2 M1-7	Anti-ROR1 mAb A2F2 M1	ROR1	SG2000	WO2021044208A1_ADC A2F2 M1-7 linker	[47]
ADC Info	WO2021044208A1 ADC A2F2-1	Anti-ROR1 mAb AB4	ROR1	SG2000	WO2021044208A1_ADC A2F2-1 linker	[47]
ADC Info	WO2021044208A1 ADC A2F2-6	Anti-ROR1 mAb A2F2	ROR1	SG2000	WO2021044208A1_ADC A2F2-6 linker	[47]
ADC Info	WO2021044208A1 ADC A2F2-7	Anti-ROR1 mAb A2F2	ROR1	SG2000	WO2021044208A1_ADC A2F2-7 linker	[47]
ADC Info	WO2021044208A1 ADC A2F3-1	Anti-ROR1 mAb A2F2	ROR1	SG2000	WO2021044208A1_ADC A2F3-1 linker	[47]
ADC Info	WO2021044208A1 ADC A2F3-6	Anti-ROR1 mAb A2F3	ROR1	SG2000	WO2021044208A1_ADC A2F3-6 linker	[47]
ADC Info	WO2021044208A1 ADC A2F3-7	Anti-ROR1 mAb A2F3	ROR1	SG2000	WO2021044208A1_ADC A2F3-7 linker	[47]
ADC Info	WO2021044208A1 ADC AB4-1	Anti-ROR1 mAb 2A2	ROR1	SG2000	WO2021044208A1_ADC AB4-1 linker	[47]
ADC Info	WO2021044208A1 ADC AB4-6	Anti-ROR1 mAb AB4	ROR1	SG2000	WO2021044208A1_ADC AB4-6 linker	[47]
ADC Info	WO2021044208A1 ADC AB4-7	Anti-ROR1 mAb AB4	ROR1	SG2000	WO2021044208A1_ADC AB4-7 linker	[47]
ADC Info	WO2021044208A1 ADC BA6-1	Anti-ROR1 mAb A2F3	ROR1	SG2000	WO2021044208A1_ADC BA6-1 linker	[47]
ADC Info	WO2021044208A1 ADC BA6-6	Anti-ROR1 mAb BA6	ROR1	SG2000	WO2021044208A1_ADC BA6-6 linker	[47]
ADC Info	WO2021044208A1 ADC BA6-7	Anti-ROR1 mAb BA6	ROR1	SG2000	WO2021044208A1_ADC BA6-7 linker	[47]
ADC Info	WO2021044208A1 ADC CC9-1	Anti-ROR1 mAb BA6	ROR1	SG2000	WO2021044208A1_ADC CC9-1 linker	[47]
ADC Info	WO2021044208A1 ADC CC9-6	Anti-ROR1 mAb CC9	ROR1	SG2000	WO2021044208A1_ADC CC9-6 linker	[47]
ADC Info	WO2021044208A1 ADC CC9-7	Anti-ROR1 mAb CC9	ROR1	SG2000	WO2021044208A1_ADC CC9-7 linker	[47]
ADC Info	WO2021044208A1 ADC D2B12-1	Anti-ROR1 mAb DG6	ROR1	SG2000	WO2021044208A1_ADC D2B12-1 linker	[47]
ADC Info	WO2021044208A1 ADC D2B12-6	Anti-ROR1 mAb D2B12	ROR1	SG2000	WO2021044208A1_ADC D2B12-6 linker	[47]
ADC Info	WO2021044208A1 ADC D2B12-7	Anti-ROR1 mAb D2B12	ROR1	SG2000	WO2021044208A1_ADC D2B12-7 linker	[47]
ADC Info	WO2021044208A1 ADC DG6-1	Anti-ROR1 mAb CC9	ROR1	SG2000	WO2021044208A1_ADC DG6-1 linker	[47]
ADC Info	WO2021044208A1 ADC DG6-6	Anti-ROR1 mAb DG6	ROR1	SG2000	WO2021044208A1_ADC DG6-6 linker	[47]
ADC Info	WO2021044208A1 ADC DG6-7	Anti-ROR1 mAb DG6	ROR1	SG2000	WO2021044208A1_ADC DG6-7 linker	[47]
ADC Info	WO2021044208A1 ADC6	Anti-ROR1 mAb C2E3	ROR1	SG2000	WO2021044208A1_ADC6 linker	[47]
ADC Info	WO2021044208A1 ADC7	Anti-ROR1 mAb C2E3	ROR1	SG2000	WO2021044208A1_ADC7 linker	[47]
ADC Info	WO2021044208A1 ADC8	Anti-ROR1 mAb C2E3	ROR1	SG2000	WO2021044208A1_ADC8 linker	[47]
ADC Info	ZV-0508	ZV05	TPBG	Duostatin 5	C-Lock-ANN tri-peptide	[133]

References

Ref 1	Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come. Haematologica. 2019 Jan;104(1):7-9. doi: 10.3324/haematol.2018.205948.
Ref 2	Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016 Aug 25;375(8):740-53. doi: 10.1056/NEJMoa1509277. Epub 2016 Jun 12.
Ref 3	A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Clin Cancer Res. 2019 Dec 1;25(23):6986-6994.
Ref 4	Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). Eur J Med Chem. 2019 Dec 1;183:111682. doi: 10.1016/j.ejmech.2019.111682.
Ref 5	A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol. 2021 Aug 5;5(1):74.
Ref 6	SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013 Aug 22;122(8):1455-63.
Ref 7	Exposure-response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2023 Jan;91(1):1-12.
Ref 8	Anti-tumor activity of vobramitamab duocarmazine (MGC018), an investigational duocarmycin-based anti-B7-H3 antibody-drug conjugate (ADC), in preclinical neuroblastoma models. Cancer Res (2023) 83 (7_Supplement): 2981.
Ref 9	Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer. Ann Oncol. 2000 Jun;11(6):735-41.
Ref 10	A Phase 1 Trial of Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory CD22+B-Cell Acute Lymphoblastic Leukemia. Blood. 2021 ;138():-. doi: 10.1182/blood-2021-153141.
Ref 11	Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood (2022) 140 (Supplement 1): 145-149. doi: 10.1182/blood-2022-158030.
Ref 12	ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors. Cancer Res (2018) 78 (13_Supplement): 744.
Ref 13	First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT-901 as monotherapy in patients with select advanced solid tumors. Journal of Clinical Oncology 2022 40:16_suppl, TPS3157-TPS3157.
Ref 14	Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody-Drug Conjugate. Mol Cancer Ther. 2023 Jun 1;22(6):765-777. doi: 10.1158/1535-7163.MCT-22-0596.
Ref 15	Byondis biopharmaceutical company announcement; 2021
Ref 16	CStone and LegoChem Biosciences Enter Global Licensing Agreement for New Antibody Drug Conjugate; 29 Oct 2020.
Ref 17	A Study of DS-9606a in Patients With Advanced Solid Tumors; NCT05394675.
Ref 18	IKS03, a Next Generation CD19-Targeted Antibody Drug Conjugate, Shows Potent Activity in Preclinical Models of Aggressive B-Cell Lymphomas. Blood (2022) 140 (Supplement 1): 31343135.
Ref 19	A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors. Mol Cancer Ther. 2022 Apr 1;21(4):625-634.
Ref 20	TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors. Mol Oncol. 2020 Jan;14(1):54-68.
Ref 21	ABBV-011, A Novel, Calicheamicin-Based Antibody-Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors. Mol Cancer Ther. 2022 Jun 1;21(6):986-998.
Ref 22	Mechanistic and benchmarking studies of ADCT-502, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors. Cancer Res (2017) 77 (13_Supplement): 52. doi: 10.1158/1538-7445.AM2017-52.
Ref 23	Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin Cancer Res. 2009 Nov 1;15(21):6709-15. doi: 10.1158/1078-0432.CCR-09-0536. Epub 2009 Oct 13.
Ref 24	A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. Am J Hematol. 2021 May 1;96(5):E175-E179. doi: 10.1002/ajh.26136. Epub 2021 Mar 11.
Ref 25	DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Gynecol Oncol. 2021 Nov;163(2):334-341. doi: 10.1016/j.ygyno.2021.08.014. Epub 2021 Aug 25.
Ref 26	Adnectin-drug conjugates for Glypican-3-specific delivery of a cytotoxic payload to tumors. Protein Eng Des Sel. 2018 May 1;31(5):159-171. doi: 10.1093/protein/gzy013.
Ref 27	IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML. Mol Cancer Ther. 2018 Jun;17(6):1271-1279. doi: 10.1158/1535-7163.MCT-17-1077. Epub 2018 Mar 27.
Ref 28	Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab. Clin Cancer Res. 2022 May 13;28(10):2030-2037. doi: 10.1158/1078-0432.CCR-21-3712.
Ref 29	A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol Immunother. 2003 Apr;52(4):243-8.
Ref 30	BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression. Clin Cancer Res. 2021 Oct 1;27(19):5376-5388.
Ref 31	CMB-401
Ref 32	First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. Int J Cancer. 2019 Oct 1;145(7):1798-1808.
Ref 33	ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition. BMC Cancer. 2021 Jun 9;21(1):681.
Ref 34	SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study. Lung Cancer. 2020 Jul;145:126-131.
Ref 35	First-in-human study of SC-004, an antibody-drug conjugate targeting CLDN6/9, in patients with epithelial ovarian cancers. Cancer Res (2020) 80 (16_Supplement): CT124.
Ref 36	First-in-human clinical trial of SC-006, a RNF43 targeted antibody-drug conjugate, as a monotherapy and in combination with budigalimab in patients with advanced colorectal cancer. Cancer Res (2020) 80 (16_Supplement): CT167.
Ref 37	Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma. Neurooncol Adv. 2022 Dec 21;5(1):vdac183.
Ref 38	Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia. Mol Cancer Ther. 2018 Feb;17(2):554-564. doi: 10.1158/1535-7163.MCT-17-0742. Epub 2017 Nov 15.
Ref 39	Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies. Blood. 2017 Nov 2;130(18):2018-2026. doi: 10.1182/blood-2017-04-779389. Epub 2017 Sep 13.
Ref 40	SGN-CD352A: A novel humanized anti-CD352 antibody-drug conjugate for the treatment of multiple myeloma. Cancer Res (2016) 76 (14_Supplement): 1195.
Ref 41	A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma. Cancer. 2019 Apr 1;125(7):1124-1132. doi: 10.1002/cncr.31912. Epub 2019 Jan 9.
Ref 42	Introduction to the preclinical profile of SYD1875, a novel site-specifically conjugated duocarmycin-based 5T4-targeting antibody-drug conjugate. Cancer Res (2021) 81 (13_Supplement): 925.
Ref 43	A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C. Cancer Chemother Pharmacol. 2023 Apr;91(4):291-300.
Ref 44	Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecol Oncol. 2020 Sep;158(3):640-645.
Ref 45	Anti?tissue factor antibody?mediated immuno?SPECT imaging of tissue factor expression in mouse models of pancreatic cancer. Oncol Rep. 2019 Apr;41(4):2371-2378. doi: 10.3892/or.2019.7017. Epub 2019 Feb 14.
Ref 46	Evaluation of 111In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen. J Nucl Med. 2019 Mar;60(3):400-406. doi: 10.2967/jnumed.118.214403. Epub 2018 Sep 20.
Ref 47	Antibody-drug conjugate comprising antibody against human ror1, and use for the same; 2021-04-01.
Ref 48	Antibody drug conjugates, targeting cancer-expressed EGFR, exhibit potent and specific antitumor activity. Biomed Pharmacother. 2023 Jan;157:114047.
Ref 49	Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma. Pharmaceuticals (Basel). 2020 Oct 2;13(10):289. doi: 10.3390/ph13100289.
Ref 50	ANTI-cMet antibody drug conjugates and methods for their use; 2017-11-23.
Ref 51	Antibody-Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo. Bioconjug Chem. 2019 May 15;30(5):1356-1370. doi: 10.1021/acs.bioconjchem.9b00133. Epub 2019 Apr 22.
Ref 52	Introduction to basic information on ADC drug adalimumab fosimdesonide.
Ref 53	Covalent linkers in antibody-drug conjugates and methods of making and using the same.
Ref 54	Generation of DAR1 Antibody-Drug Conjugates for Ultrapotent Payloads Using Tailored GlycoConnect Technology. Bioconjug Chem. 2023 Mar 15;34(3):538-548. doi: 10.1021/acs.bioconjchem.2c00611. Epub 2023 Mar 1.
Ref 55	Preclinical development of ADCT-211, a novel pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting solid tumors expressing IL13RA2. Cancer Res (2023) 83 (7_Supplement): 1604.
Ref 56	Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodiazepine dimer SG2000 for PSMA-expressing cancers. Cancer Res (2023) 83 (7_Supplement): 2638.
Ref 57	Antibody fragment-conjugated gemcitabine and paclitaxel-based liposome for effective therapeutic efficacy in pancreatic cancer. Mater Sci Eng C Mater Biol Appl. 2018 Aug 1;89:328-335. doi: 10.1016/j.msec.2018.04.011. Epub 2018 Apr 11.
Ref 58	Antibody-Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo. Bioconjug Chem. 2019 May 15;30(5):1356-1370. doi: 10.1021/acs.bioconjchem.9b00133. Epub 2019 Apr 22.
Ref 59	Phosphate based linkers for intracellular delivery of drug conjugates; 2015-10-08.
Ref 60	New Senolysis Approach via Antibody-Drug Conjugate Targeting of the Senescent Cell Marker Apolipoprotein D for Skin Rejuvenation. Int J Mol Sci. 2023 Mar 20;24(6):5857. doi: 10.3390/ijms24065857.
Ref 61	Introduction to basic information on anti-B4 monoclonal antibody-DC1 conjugate (Anti-B4-DC1).
Ref 62	Bcma monoclonal antibody-drug conjugate.
Ref 63	An Anti-CD22-seco-CBI-Dimer Antibody-Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models. Mol Cancer Ther. 2021 Feb;20(2):340-346.
Ref 64	A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30(+) lymphomas. Mol Oncol. 2018 Mar;12(3):339-355. doi: 10.1002/1878-0261.12166. Epub 2018 Jan 26.
Ref 65	Design, Synthesis, and Structure-Activity Relationships of Novel Tetrahydroisoquinolino Benzodiazepine Dimer Antitumor Agents and Their Application in Antibody-Drug Conjugates. J Med Chem. 2020 Nov 25;63(22):13913-13950. doi: 10.1021/acs.jmedchem.0c01385.
Ref 66	An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia. Clin Cancer Res. 2019 Feb 15;25(4):1358-1368. doi: 10.1158/1078-0432.CCR-18-0333. Epub 2018 Jun 29.
Ref 67	High-Affinity Human Anti-c-Met IgG Conjugated to Oxaliplatin as Targeted Chemotherapy for Hepatocellular Carcinoma. Front Oncol. 2019 Aug 2;9:717. doi: 10.3389/fonc.2019.00717. eCollection 2019.
Ref 68	Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers. Mol Pharm. 2019 Dec 2;16(12):4817-4825. doi: 10.1021/acs.molpharmaceut.9b00696. Epub 2019 Oct 29.
Ref 69	ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. Blood Adv. 2020 Oct 27;4(20):5203-5214. doi: 10.1182/bloodadvances.2020002395.
Ref 70	Design considerations of an IL13R2 antibody-drug conjugate for diffuse intrinsic pontine glioma. Acta Neuropathol Commun. 2021 May 17;9(1):88. doi: 10.1186/s40478-021-01184-9.
Ref 71	Bispecific anti-mPDGFR x cotinine scFv-C()-scFv fusion protein and cotinine-duocarmycin can form antibody-drug conjugate-like complexes that exert cytotoxicity against mPDGFR expressing cells. Methods. 2019 Feb 1;154:125-135. doi: 10.1016/j.ymeth.2018.10.002. Epub 2018 Oct 4.
Ref 72	APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo. Mol Cancer Ther. 2019 Feb;18(2):335-345. doi: 10.1158/1535-7163.MCT-18-0842. Epub 2018 Nov 9.
Ref 73	Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker. Sci Rep. 2021 Oct 13;11(1):20358. doi: 10.1038/s41598-021-99852-2.
Ref 74	Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer. J Med Chem. 2012 Jan 26;55(2):766-82.
Ref 75	Generation and preclinical characterization of CD123-CPI antibody-drug conjugate (ADC). Cancer Res (2018) 78 (13_Supplement): 935.
Ref 76	CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity. J Immunother Cancer. 2020 Sep;8(2):e000860. doi: 10.1136/jitc-2020-000860.
Ref 77	Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia. Clin Cancer Res. 2021 Jan 15;27(2):622-631. doi: 10.1158/1078-0432.CCR-20-2149. Epub 2020 Nov 4.
Ref 78	An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma. Sci Transl Med. 2019 Mar 13;11(483):eaau9732. doi: 10.1126/scitranslmed.aau9732.
Ref 79	A new class of DNA sequence-selective G-A cross-linking antibody-drug conjugate (ADC) payloads. Cancer Res (2022) 82 (12_Supplement): 1749.
Ref 80	Aptamer-Directed Conjugation of DNA to Therapeutic Antibodies. Bioconjug Chem. 2019 Aug 21;30(8):2127-2135. doi: 10.1021/acs.bioconjchem.9b00363. Epub 2019 Jul 12.
Ref 81	cIRCR201-dPBD, a Novel Pyrrolobenzodiazepine Dimer-Containing Site-Specific Antibody-Drug Conjugate Targeting c-Met Overexpression Tumors. ACS Omega. 2020 Sep 29;5(40):25798-25809. doi: 10.1021/acsomega.0c03102.
Ref 82	CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Adv. 2018 Jul 24;2(14):1738-1749. doi: 10.1182/bloodadvances.2018020107.
Ref 83	In Vivo Activation of Duocarmycin-Antibody Conjugates by Near-Infrared Light. ACS Cent Sci. 2017 Apr 26;3(4):329-337. doi: 10.1021/acscentsci.7b00026. Epub 2017 Feb 24.
Ref 84	Duocarmycin-based antibody-drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress. Drug Discov Today. 2021 Aug;26(8):1857-1874. doi: 10.1016/j.drudis.2021.06.012. Epub 2021 Jul 3.
Ref 85	A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope. Cell Rep Med. 2021 Jul 21;2(7):100344.
Ref 86	Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic cancer. Cancer Med. 2019 Feb;8(2):643-655. doi: 10.1002/cam4.1974. Epub 2019 Jan 25.
Ref 87	Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody-Drug Conjugates (ADCs). ACS Med Chem Lett. 2019 Jul 22;10(8):1211-1215. doi: 10.1021/acsmedchemlett.9b00254. eCollection 2019 Aug 8.
Ref 88	Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma. Oncotarget. 2017 Jul 22;8(36):60368-60377. doi: 10.18632/oncotarget.19499. eCollection 2017 Sep 1.
Ref 89	Synthesis and in vitro evaluation of SG3227, a pyrrolobenzodiazepine dimer antibody-drug conjugate payload based on sibiromycin. Bioorg Med Chem Lett. 2017 Mar 1;27(5):1154-1158.
Ref 90	EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors. Pharmaceutics. 2021 Apr 2;13(4):483. doi: 10.3390/pharmaceutics13040483.
Ref 91	A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer. Drug Deliv. 2022 Dec;29(1):1243-1256.
Ref 92	Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer. Oncotarget. 2018 May 1;9(33):22960-22975. doi: 10.18632/oncotarget.25160. eCollection 2018 May 1.
Ref 93	An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer. Br J Cancer. 2023 Apr;128(8):1592-1602. doi: 10.1038/s41416-023-02192-3. Epub 2023 Feb 9.
Ref 94	TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors. Mol Oncol. 2020 Jan;14(1):54-68. doi: 10.1002/1878-0261.12600. Epub 2019 Dec 3.
Ref 95	Intratumoral Payload Concentration Correlates with the Activity of Antibody-Drug Conjugates. Mol Cancer Ther. 2018 Mar;17(3):677-685. doi: 10.1158/1535-7163.MCT-17-0697. Epub 2018 Jan 18.
Ref 96	Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload. ACS Med Chem Lett. 2016 May 24;7(11):983-987.
Ref 97	Preclinical activity of hLL2-PBD, a novel anti-CD22 antibody-pyrrolobenzodiazepine (PBD) conjugate in models of non-Hodgkin lymphoma. Cancer Res (2015) 75 (15_Supplement): 637.
Ref 98	Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof; 2017-10-19.
Ref 99	Anti-huLRRC15 antibody drug conjugates and methods for their use. 2017-06-08
Ref 100	The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Haematologica. 2019 Aug;104(8):1633-1639. doi: 10.3324/haematol.2018.211011. Epub 2019 Feb 7.
Ref 101	Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res. 1995 Sep 15;55(18):4079-84.
Ref 102	Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma. Hepatology. 2019 Aug;70(2):563-576. doi: 10.1002/hep.30326. Epub 2019 Feb 19.
Ref 103	IKS01, a next generation antibody drug conjugate, shows target-dependent efficacy in a platinum-resistant tumor model with low levels of folate receptor alpha expression. Mol Cancer Ther (2019) 18 (12_Supplement): C023.
Ref 104	ADC review IPH43
Ref 105	ADC review: basic information about KTN0182A.
Ref 106	Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C. Biochem Biophys Res Commun. 2006 Oct 20;349(2):816-24. doi: 10.1016/j.bbrc.2006.08.114. Epub 2006 Aug 28.
Ref 107	The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. Clin Cancer Res. 2021 May 15;27(10):2938-2946. doi: 10.1158/1078-0432.CCR-20-4221. Epub 2021 Feb 22.
Ref 108	Adagene and ADC therapeutics announce SAFEbody license agreement; 2019
Ref 109	Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4. Mol Cancer Ther. 2017 Aug;16(8):1576-1587. doi: 10.1158/1535-7163.MCT-16-0825. Epub 2017 May 18.
Ref 110	Pharmacokinetics and tissue distribution of cisplatin and conjugates of cisplatin with carboxymethyldextran and A5B7 monoclonal antibody in CD1 mice. J Pharm Sci. 1997 Dec;86(12):1478-83. doi: 10.1021/js960282u.
Ref 111	1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment.
Ref 112	Nanovalent pharmaceuticals product pipeline
Ref 113	Aryl Sulfate is a Useful Motif for Conjugating and Releasing Phenolic Molecules: Sulfur Fluorine Exchange Click Chemistry Enables Discovery of Ortho-Hydroxy-Protected Aryl Sulfate Linker. Bioconjug Chem. 2019 Jul 17;30(7):1957-1968. doi: 10.1021/acs.bioconjchem.9b00340. Epub 2019 Jun 28.
Ref 114	Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy. J Immunother Cancer. 2019 Sep 13;7(1):250. doi: 10.1186/s40425-019-0732-8.
Ref 115	Natural Product Bis-Intercalator Depsipeptides as a New Class of Payloads for Antibody-Drug Conjugates. Bioconjug Chem. 2019 Jan 16;30(1):200-209. doi: 10.1021/acs.bioconjchem.8b00843. Epub 2018 Dec 13.
Ref 116	Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models. Oncotarget. 2017 Dec 26;9(4):5197-5207. doi: 10.18632/oncotarget.23708. eCollection 2018 Jan 12.
Ref 117	Pyxis oncology presents preclinical data and details on antibody-drug conjugate candidates supporting therapeutic potential
Ref 118	Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment. Int Immunopharmacol. 2018 Sep;62:299-308. doi: 10.1016/j.intimp.2018.06.034. Epub 2018 Jul 23.
Ref 119	Introduction to basic information on recombinant humanized anti-EGFR mAb-DUO-5 conjugate(Zova Biotherapeutics/Zhejiang Hisun Pharmaceutical).
Ref 120	Introduction to basic information on ADC drug REGN3124-PBD.
Ref 121	Novel antibody conjugates and uses thereof; 2014-08-28.
Ref 122	Anti-tumor activity of antibody drug conjugate targeting aspartate--hydroxylase in pancreatic ductal adenocarcinoma. Cancer Lett. 2019 May 1;449:87-98. doi: 10.1016/j.canlet.2019.02.006. Epub 2019 Feb 12.
Ref 123	Site-specific conjugation of linker drugs to antibodies and resulting adcs.
Ref 124	Uncialamycin-based antibody-drug conjugates: Unique enediyne ADCs exhibiting bystander killing effect. Proc Natl Acad Sci U S A. 2021 Jun 22;118(25):e2107042118. doi: 10.1073/pnas.2107042118.
Ref 125	A single dose of antibody-drug conjugate cures a stage 1 model of African trypanosomiasis. PLoS Negl Trop Dis. 2019 May 23;13(5):e0007373. doi: 10.1371/journal.pntd.0007373. eCollection 2019 May.
Ref 126	Design, Synthesis, and Bioevaluation of a Novel Hybrid Molecular Pyrrolobenzodiazepine-Anthracenecarboxyimide as a Payload for Antibody-Drug Conjugate. J Med Chem. 2022 Sep 8;65(17):11679-11702. doi: 10.1021/acs.jmedchem.2c00471. Epub 2022 Aug 18.
Ref 127	BN 80245: An E-ring modified camptothecin with potent antiproliferative and topoisomerase I inhibitory activities. Bioorg Med Chem Lett. 1997;7(17):2235-2238.
Ref 128	Enzymatic glycan remodeling-metal free click (GlycoConnect) provides homogenous antibody-drug conjugates with improved stability and therapeutic index without sequence engineering. MAbs. 2022 Jan-Dec;14(1):2078466.
Ref 129	Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer. MAbs. 2019 Apr;11(3):500-515.
Ref 130	Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual -glucuronide and dipeptide triggers. Eur J Med Chem. 2019 Oct 1;179:591-607.
Ref 131	Internalization of Foldamer-Based DNA Mimics through a Site-Specific Antibody Conjugate to Target HER2-Positive Cancer Cells. Pharmaceuticals (Basel). 2021 Jun 28;14(7):624. doi: 10.3390/ph14070624.
Ref 132	Pyrrolobenzodiazepines and conjugates thereof; 2013-04-18.
Ref 133	Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker. Cancer Med. 2019 Apr;8(4):1793-1805. doi: 10.1002/cam4.2066. Epub 2019 Mar 7.

Target Information

Citation

Visitor Map

Correspondence

Prof. Feng ZHU (zhufeng@zju.edu.cn)

Prof. Xiaowu DONG (dongxw@zju.edu.cn)

Prof. Luo FANG (fangluo@zjcc.org.cn)